Cancer biotech Surface Oncology sets terms for $84 million IPO

Shutterstock photo

Surface Oncology, a clinical-stage biotech developing next-generation antibody cancer therapies, announced terms for its IPO on Monday.

The Cambridge, MA-based company plans to raise $84 million by offering 6 million shares at a price range of $13 to $15. Insiders intend to purchase $25 million (30% of deal size) worth of shares in the offering. In addition, Novartis intends to invest $11.5 million in a concurrent private placement. At the midpoint of the proposed range, Surface Oncology would command a fully diluted market value of $404 million.

Surface Oncology was founded in 2014 and booked $13 million in sales for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol SURF. Goldman Sachs, Cowen & Company and Evercore ISI are the joint bookrunners on the deal. It is expected to price during the week of April 16, 2018.

The article Cancer biotech Surface Oncology sets terms for $84 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?